Milestone Pharmaceuticals Says FDA Issued Complete Response Letter Regarding Its New Drug Application For CARDAMYST Nasal Spray
Benzinga Newsdesk 1 year ago
NewsFDA
The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufacturing and Controls (CMC) issues to be addressed.
The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufacturing and Controls (CMC) issues to be addressed.